Past, present, and future therapies for clostridium difficile-associated disease

Annals of Pharmacotherapy

Volumn 40, Issue 12, 2006, Pages 2155-2163

  Surowiec, Dorothy ^a,e   Kuyumjian, Arpi G ^b   Wynd, Michael A ^b,c   Cicogna, Cristina E ^b,d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Clostridium difficile associated disease; Metronidazole; Vancomycin

Indexed keywords

AMINOPENICILLIN; ANTIBIOTIC AGENT; BACITRACIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COLESTIPOL; COLESTYRAMINE; ENEMA; FUSIDIC ACID; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; ION EXCHANGE RESIN; METRONIDAZOLE; NITAZOXANIDE; POLYMER; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAXIMIN; TEICOPLANIN; TOLEVAMER; UNINDEXED DRUG; VACCINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISEASE ASSOCIATION; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG TREATMENT FAILURE; ENVIRONMENTAL SANITATION; HOSPITAL HYGIENE; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MEDICAL LITERATURE; MEDLINE; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VACCINATION;

CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FORECASTING; HUMANS; METRONIDAZOLE; PROBIOTICS; RECURRENCE; VANCOMYCIN;

EID: 33845634379     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H332     Document Type: Article

References (103)

1. Poutanen SM, Simor AE. Clostridium difficile associated diarrhea in adults. CMAJ 2004;171:51-7.
2. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
3. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-15.
4. Muto C, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80.
5. Wong SS, Woo PC, Luk WK, Yuen KY. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and E test. Diagn Microbiol Infect Dis 1999;34:1-6.
6. Barbut F, Decre D, Burghoffer B, et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999;43:2607-11.
7. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586-90.
8. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5:549-57.
9. Gerding DN. Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis 2005;40:1598-600.
10. Pelaez T, Alonso AR, Martin-Lopez A, Garcia-Arias V, Marin M, Bouza E. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005;49:1157-9.
11. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
12. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-84.
13. Owens R. Clostridium difficile associated disease: an emerging threat to patient safety. Pharmacotherapy 2006;26:299-311.
14. Bouza E, Munoz P, Alonso R. Clinical manifestations, treatment, and control of infections caused by Clostridium difficile. Clin Microbiol Infect 2005;11(suppl 4):57-64.
15. Bartlett JG, Perl TM. The new Clostridium difficile - what does it mean? N Engl J Med 2005;353:2503-5.
16. Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002;23:137-40.
17. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999;341:1645-51.
18. McCusker ME, Harris AD, Perencevich E, Roghmann M. Fluoroquinolone use and Clostridium difficile associated diarrhea. Emerg Infect Dis 2003;9:730-2.
19. Brown E, Talbot GH, Axelrod P. Risk factors for Clostridium difficile toxin associated diarrhea. Infect Control Hosp Epidemiol 1990;11:283-90.
20. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile associated disease. JAMA 2005;294:2989-95.
21. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors; cohort and case-control studies. CMAJ 2004;171:33-8.
22. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhea. J Hosp Infect 2003;54:243-5. DOI 10.1016/S0195-670(03)00088-4
23. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006;24:613-9.
24. Dial JA, Delaney C, Schneider V, Suissa S. Proton pump inhibitor use and risk of community acquired Clostridium difficile associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006;175:745-8.
25. Wanahita A, Goldsmith EA, Marino BJ, Musher DM. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 2003;115:543-6.
26. Chang TW, Lauermann M, Bartlett JG. Cytotoxicity assay in antibiotic-associated colitis. J Infect Dis 1979;140:765-70.
27. Lozniewski A, Rabaud C, Dotto E, Weber M, Mory F. Laboratory diagnosis of Clostridium difficile associated diarrhea and colitis: usefulness of Premier Cytoclone A + B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains. J Clin Microbiol 2001;39:1996-8.
28. Alonso R, Munoz C, Gros S, Garcia de Viedma D, Pelaez T, Bouza E. Rapid detection of toxigenic Clostridium difficile from stool samples by a nested PCR of toxin B gene. J Hosp Meet 1999;41:145-9.
29. Rupnik M. How to detect Clostridium difficile variant strains in a routine laboratory. Clin Microbiol Infect 2001;7:417-20.
30. Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006;73:187-97.
31. Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 2002;62:2177-84.
32. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363-72.
33. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. Ann Intern Med 1992;117:297-302.
34. Novak EM, Lee JG, Seckman CE, Phillips JP, DiSanto AR. Unfavorable effect of atropine-diphenoxylate therapy in lincomycin-caused diarrhea. JAMA 1976;235:1451-4.
35. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health Syst Pharm 1998;55:1407-11.
36. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995;44(RR-12):1-13.
37. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993;269:71-5.
38. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile associated diarrhea. Clin Infect Dis 1996;22:813-8.
39. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhea and colitis. Lancet 1983;2:1043-6.
40. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of recurrence after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-7.
41. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile associated disease. J Clin Gastroenterol 2004;38:414-8.
42. Modena S, Gollamudi S, Friedenberg F. Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile associated diarrhea. J Clin Gastroenterol 2006;40:49-54.
43. Young GP, Ward PB, Bayley N, et al. Antimicrobial-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985;89:1038-45.
44. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002;35:690-6.
45. Nathanson DR, Sheahan M, Chao L, Wallack MK. Intracolonic use of vancomycin for treatment of Clostridium difficile colitis in a patient with a diverted colon. Dis Colon Rectum 2001;44:1871-2.
46. Friedenberg F, Fernandez A, Kaul V, Niami P, Levine GM. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001;44:1176-80.
47. Gerding DN. Treatment of Clostridium difficile-associated diarrhea and colitis. Curr Topics Microbiol Immunol 2000;250:127-39.
48. Bradbury AW, Barret S. Surgical aspects of Clostridium difficile colitis. Br J Surg 1997;84:150-9.
49. Taylor NS, Bartlett JG. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 1980;141:92-7.
50. Pantosti A, Luzzi I, Cardines R, Gianfrilli P. Comparison of the in vitro activities of teicoplanin and vancomycin against Clostridium difficile and their interactions with cholestyramine. Antimicrob Agents Chemother 1985;28:847-8.
51. Moncino MD, Falletta JM. Multiple relapses of Clostridium difficile associated diarrhea in a cancer patient: successful control with long-term cholestyramine therapy. Am J Pediatr Hematol Oncol 1992;14:361-4.
52. Pruksananonda P, Powell KR. Multiple relapses of Clostridium difficile associated diarrhea responding to an extended course of cholestyramine. Pediatr Infect Dis J 1989;8:175-8.
53. Kunimoto D, Thomson ABR. Recurrent Clostridium difficile associated colitis responding to cholestyramine. Digestion 1986;33:225-8.
54. Mogg GAG, George RH, Youngs D, et al. Randomized controlled trial of colestipol in antibiotic associated colitis. Br J Surg 1982;69:137-9.
55. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003;36:580-5.
56. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhea in six patients. Lancet 1989;27:1156-60.
57. Schwan A, Sjolin S, Trottestam U, Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal feces. Scand J Infect Dis 1984;16:211-5.
58. Bowden TA, Mansberger AR, Lykins LE. Pseudomembranous enterocolitis: mechanism of restoring floral homeostasis. Am Surgeon 1981;47:178-83.
59. Liacouras CA, Piccoli DA. Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis. J Clin Gastroenterol 1996;22:186-9.
60. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390-7.
61. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet 2001;357:189-93.
62. Leung DM, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991;118:633-7.
63. Warny M, Denie C, Delmee M, Lefebvre C. Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A. Acta Clin Belg 1995;50:36-9.
64. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997;41:366-70.
65. Beales IL. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhea (letter). Gut 2002;51:456.
66. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhea. J Antimicrob Chemother 2004;53:882-4.
67. Murphy C, Vernon M, Cullen M. Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing 2006;35:85-6. DOI 10.1093/ageing/afi212
68. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006;49:1-6.
69. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000;44:2254-8.
70. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-7.
71. VA Medical Center, Houston; Baylor College of Medicine. Compassionate use of nitazoxanide for the treatment of Clostridium difficile colitis in patients who have failed conventional therapy. www.clinicaltrials.gov/ct/show/NCT00304356 (accessed 2006 May 16).
72. VA Medical Center, Houston; Baylor College of Medicine. Vancomycin vs. nitazoxanide to treat recurrent Clostridium difficile colitis that has failed therapy with metronidazole. www.clinicaltrials.gov/ct/show/NCT00304889 (accessed 2006 May 16).
73. Nomura K, Matsumoto Y, Toshida N, et al. Successful treatment with rifampin for fulminant antibiotics associated colitis in a patient with non-Hodgkin's lymphoma. World J Gastroenterol 2004;10:765-6.
74. Buggy BP, Fekety R, Silva J. Therapy of relapsing Clostridium difficile associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 1987;9:155-9.
75. Anton PM, O'Brian M, Kokkotou E, et al. Rifazil treats and prevents recurrence of Clostridium difficile-associated diarrhea in hamsters. Antimicrob Agents Chemother 2004;48:3975-9.
76. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antimicrobial: pharmacology and clinical potential. Chemotherapy 2005;51(suppl 1):36-66.
77. Salix Pharmaceuticals. A trial to compare xifaxan to vancomycin for the treatment of Clostridium difficile-associated diarrhea (CAD). www. clinicaltrials.gov/ct/guishow/NCT00269399 (accessed 2006 May 16).
78. Kurtz CB, Cannon P, Brezzani A, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 2001;45:2340-7.
79. Davidson D, Peppe J, Louie T. A phase 2 study of the toxin binding polymer tolevamer in patients with Clostridium difficile associated diarrhea. Presented at: First International Clostridium difficile Symposium, Slovenia, May 5-8, 2004.
80. Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:411-20.
81. Genzyme. A study of GT267-004 versus vancomycin, and GT267-004 versus metronidazole, in patients with Clostridium difficile-associated diarrhea. www.clinicaltrials.gov/ct/show/NCT00106509(accessed 2006 May 16).
82. Wilcox MH, Fawley WN, Settle CD, Davidson A. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? J Hosp Infect 1998;38:93-100.
83. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile associated diarrhea. J Clin Microbiol 2000;38:2386-8.
84. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile associated disease in Quebec, Canada. Clin Infect Dis 2006;42:758-64.
85. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:43-50.
86. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97:1769-75.
87. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antimicrobial-associated pseudomembranous colitis. Am J Gastroenterol 1985;80:867-8.
88. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in the prevention of antimicrobial associated diarrhea: meta-analysis. BMJ 2002;324:1361-7.
89. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812-22.
90. Niault M, Thomas F, Prost J, Ansari FH, Kalfon P. Fungemia due to Saccharomyces species in a patient treated with enteral S. boulardii. Clin Infect Dis 1999;28:930.
91. Harty DW, Oakey HJ, Knox KW. Pathogenic potential of lactobacilli. Int J Food Microbiol 1994;24:179-89.
92. Schlegel L, Lemerle S, Greslin P. Lactobacillus species as opportunistic pathogens in immune-compromised patients. Eur J Clin Microbiol Infect Dis 1998;17:887-8.
93. Kelly CP, Chetham S, Keates S, et al. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother 1997;41:236-41.
94. Warny M, Fatimi A, Bostwick EF, et al. Bovine immunoglobulin concentrate-Clostridium difficile retains C. difficile toxin neutralizing activity after passage through the human stomach and small intestine. Gut 1999;44:212-7.
95. Van Dissel JT, de Groot N, Hensgens CM, et al. Bovine antibody-enriched whey to aid in the prevention of relapse of Clostridium difficile associated diarrhea: preclinical and preliminary clinical data. J Med Microbiol 2005;54:197-205.
96. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001;69:988-95. DOI 10.1128/IAI.69.2.988-995.2001
97. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile associated diarrhea and cost. Ann Intern Med 1998;128:989-95.
98. Khan R, Cheesbrough J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhea (CDAD) over a five-year period in a district general hospital. J Hosp Infect 2003;54:104-8.
99. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J. Shea position paper: Clostridium difficile associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459-77.
100. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial trans-mission. Am J Med 1990;88:137-40.
101. Clostridium difficile information for healthcare providers; 2004 (updated 2005 July 7). Centers for Disease Control and Prevention, www.cdc.gov/ncidod/ dhqp/id_CdiffFAQ_HCP.html (accessed 2006 Mar 7).
102. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPA/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 2002;23(12 suppl):S3-40.
103. Wilcox MH, Fawley WN, Wigglesworth N, Parnell P, Verity P, Freeman J. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 2003;54:109-14.